Plasma soluble C-type lectin-like receptor-2 is associated with the risk of coronary artery disease
Plasma soluble C-type lectin-like receptor-2 is associated with the risk of coronary artery disease
复制标题
血浆可溶性 C 型凝集素样受体 2 与冠状动脉疾病的风险相关
DOI：
10.1007/s11684-019-0692-x
复制
发表时间：
2020-02-01
影响因子：
8.1
通讯作者：
Zhu, Li
中科院分区：
文献类型：
--
作者：
Fei, Min;Xiang, Li;Zhu, Li
越来越多的证据表明，C型凝集素样受体-2（CLEC-2）在动脉粥样硬化血栓形成中起重要作用。在本病例对照研究中，我们调查了CLEC-2与冠状动脉疾病（CAD）发病率之间的关系。共纳入216例患者，包括14例稳定型心绞痛（SAP，非ACS）和202例急性冠状动脉综合征（ACS）患者，以及89例非CAD对照者。采用酶联免疫吸附试验（ELISA）测定血浆可溶性CLEC-2（sCLEC-2）水平。与对照组（65.69（55.36-143.22）pg/mL）相比，冠心病组（133.67（88.76-220.09）pg/mL）和急性冠脉综合征组（134.16（88.88-225.81）pg/mL）血浆sCLEC-2水平显著升高。sCLEC-2每增加1个四分位数，CAD的多变量校正比值比（95%置信区间）达到2.01（1.52-2.66）（Ptrend< 0.001）。限制性三次样条曲线显示sCLEC 2与CAD发病率呈正剂量反应关系（P线性< 0.001）。将sCLEC-2加入到传统危险因素中，可提高冠心病的C统计量（0.821vs.0.761，P = 0.004）和再分类能力（净再分类提高：57.45%，P < 0.001;综合辨别力提高：8.27%，P < 0.001）。总之，高血浆sCLEC-2与CAD风险独立相关，sCLEC-2的预后价值可在未来的前瞻性研究中评估。
Accumulating evidence suggests that C-type lectin-like receptor-2 (CLEC-2) plays an important role in atherothrombosis. In this case-control study, we investigated the association between CLEC-2 and incidence of coronary artery disease (CAD). A total of 216 patients, including 14 cases of stable angina pectoris (SAP, non-ACS) and 202 cases of acute coronary syndrome (ACS), and 89 non-CAD control subjects were enrolled. Plasma levels of soluble CLEC-2 (sCLEC-2) were measured using the enzyme-linked immunosorbent assay (ELISA). Compared with the control group (65.69 (55.36–143.22) pg/mL), the plasma levels of sCLEC-2 were significantly increased in patients with CAD (133.67 (88.76–220.09) pg/mL) and ACS (134.16 (88.88–225.81) pg/mL). The multivariate adjusted odds ratios (95% confidence interval) of CAD reached 2.01 (1.52–2.66) (Ptrend< 0.001) for each 1-quartile increase in sCLEC-2. Restricted cubic splines showed a positive dose-response association between sCLEC2 and CAD incidence (Plinearity< 0.001). The addition of sCLEC-2 to conventional risk factors improved the C statistic (0.821 vs. 0.761,P= 0.004) and reclassification ability (net reclassification improvement: 57.45%,P< 0.001; integrated discrimination improvement: 8.27%,P< 0.001) for CAD. In conclusion, high plasma sCLEC-2 is independently associated with CAD risk, and the prognostic value of sCLEC-2 may be evaluated in future prospective studies.